e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Reference, reliability and risk: advances in lung function
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Spirometry quality in patients with COPD exacerbation, related to the “frequent exacerbator” phenotype
I. Strambu, D. Ionita, I. Stoicescu, M. Burecu, D. Dospinoiu, C. Nita, A. Croitoru, F. Cojocaru (Bucharest, Romania)
Source:
Annual Congress 2013 –Reference, reliability and risk: advances in lung function
Session:
Reference, reliability and risk: advances in lung function
Session type:
Oral Presentation
Number:
1792
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Strambu, D. Ionita, I. Stoicescu, M. Burecu, D. Dospinoiu, C. Nita, A. Croitoru, F. Cojocaru (Bucharest, Romania). Spirometry quality in patients with COPD exacerbation, related to the “frequent exacerbator” phenotype. Eur Respir J 2013; 42: Suppl. 57, 1792
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
A 12-year-old male child with fever, productive cough and sudden onset paralysis
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
The clinical significance and frequency of bronchiectasis in COPD patients
Source: International Congress 2016 – Monitoring comorbidities
Year: 2016
Clinical characteristics of patients with clinically-diagnosed COPD exacerbations but without concomitant airflow limitation
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015
Lung function change and exacerbations in patients with COPD in the WISDOM study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Can emphysema predict exacerbations and changes in PFTs in COPD?
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
Frequency of COPD exacerbations and severity of COPD
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
Irisin is associated with severe exacerbations of COPD independently of lung function, comorbidities and exercise capacity
Source: International Congress 2015 – Notable abstracts in COPD: variety
Year: 2015
Static hyperinflation and respiratory disability were associated with frequent-exacerbation phenotype in patients with severe COPD
Source: International Congress 2016 – Exploring mechanisms in health and disease
Year: 2016
The bronchitic phenotype is associated with frequent exacerbations in COPD irrespective of chronic bacterial airway infection
Source: Annual Congress 2013 –Guidelines and exacerbations
Year: 2013
The relation of comorbidities with the exacerbation severity in patients with COPD
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
Symptom profile of exacerbations in earlier and later COPD
Source: Annual Congress 2013 –Asthma and COPD: diseases with different phenotypes
Year: 2013
Impact of frequent exacerbations in patients with COPD
Source: International Congress 2014 – Clinical presentations
Year: 2014
COPD on anti-GERD therapy remains at higher risk for severe exacerbation
Source: International Congress 2014 – COPD exacerbations
Year: 2014
The most frequent comorbidies in COPD and their inflence on the prognosis of the disease
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Eosinophilia as marker of outcome in hospitalised patients with AECOPD
Source: Annual Congress 2013 –COPD and infections
Year: 2013
Real life assessment of inhaler use and acute exacerbations in 2935 COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
A global survey conducted to determine frequency of exacerbations in COPD patients
Source: Annual Congress 2013 –COPD treatment
Year: 2013
Difficulty in management of COPD exacerbation: Is this chronic exacerbation or difficult COPD: “A specific phenotype?”
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
Characterization of readmissions in patients hospitalized with COPD exacerbation
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept